VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
VTAE was delisted on the 24th of October, 2016.
71 hedge funds and large institutions have $227M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 39 increasing their positions, 12 reducing their positions, and 17 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 12
66% more capital invested
Capital invested by funds: $137M → $227M (+$90.4M)
9% less funds holding
Funds holding: 78 → 71 (-7)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.1M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.59M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.85M |
| 4 |
CCM
Century Capital Management
Boston,
Massachusetts
|
+$1.69M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$1.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$11.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.59M |
| 3 |
MC
Mitra Capital
Boston,
Massachusetts
|
-$2.97M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.49M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$2.09M |
VTAE Hedge Fund Activity: Q2 2016 in Review
71 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q2 2016, worth a combined $227M — up 66% from $137M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of VTAE and 11 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 39 added.
The largest buyer was Fidelity Investments, adding an estimated $14.1M. The largest seller was BVF Inc, cutting an estimated $11.4M.
- 71 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q2 2016, down from 78 in Q1 2016.
- Funds reported $227M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q2 2016, up 66% quarter-over-quarter.
- 11 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q2 2016 and 17 closed out, a net change of -6 holders.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q2 2016 was Fidelity Investments, an estimated $14.1M added.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q2 2016 was BVF Inc, an estimated $11.4M sold.
Based on aggregated 13F filings for Q2 2016.